Literature DB >> 35343593

Using magnetic resonance fingerprinting to characterize periventricular nodular heterotopias in pharmacoresistant epilepsy.

Joon Yul Choi1, Balu Krishnan1, Siyuan Hu2, David Martinez1, Yinging Tang1,3, Xiaofeng Wang4, Ken Sakaie5, Stephen Jones5, Hiroatsu Murakami1, Ingmar Blümcke1,6, Imad Najm1, Dan Ma2, Zhong Irene Wang1.   

Abstract

OBJECTIVE: We aimed to use a novel magnetic resonance fingerprinting (MRF) technique to examine in vivo tissue property characteristics of periventricular nodular heterotopia (PVNH). These characteristics were further correlated with stereotactic-electroencephalographic (SEEG) ictal onset findings.
METHODS: We included five patients with PVNH who had SEEG-guided surgery and at least 1 year of seizure freedom or substantial seizure reduction. High-resolution MRF scans were acquired at 3 T, generating three-dimensional quantitative T1 and T2  maps. We assessed the differences between T1 and T2  values from the voxels in the nodules located in the SEEG-defined seizure onset zone (SOZ) and non-SOZ, on -individual and group levels. Receiver operating characteristic analyses were performed to obtain the optimal classification performance. Quantification of SEEG ictal onset signals from the nodules was performed by calculating power spectrum density (PSD). The association between PSD and T1 /T2  values was further assessed at different frequency bands.
RESULTS: Individual-level analysis showed T1 was significantly higher in SOZ voxels than non-SOZ voxels (p < .05), with an average 73% classification accuracy. Group-level analysis also showed higher T1 was significantly associated with SOZ voxels (p < .001). At the optimal cutoff (normalized T1 of 1.1), a 76% accuracy for classifying SOZ nodules from non-SOZ nodules was achieved. T1  values were significantly associated with ictal onset PSD at the ultraslow, θ, β, γ, and ripple bands (p < .05). T2  values were significantly associated with PSD only at the ultraslow band (p < .05). SIGNIFICANCE: Quantitative MRF measures, especially T1 , can provide additional noninvasive information to separate nodules in SOZ and non-SOZ. The T1 and T2 tissue property changes carry electrophysiological underpinnings relevant to the epilepsy, as shown by their significant positive associations with power changes during the SEEG seizure onset. The use of MRF as a supplementary noninvasive tool may improve presurgical evaluation for patients with PVNH and pharmacoresistant epilepsy.
© 2022 International League Against Epilepsy.

Entities:  

Keywords:  MR fingerprinting; T1 relaxation time; magnetic resonance imaging; periventricular nodular heterotopia; stereotactic electroencephalography

Mesh:

Year:  2022        PMID: 35343593      PMCID: PMC9081261          DOI: 10.1111/epi.17191

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   6.740


  47 in total

Review 1.  Malformations of cortical development and epilepsy.

Authors:  R I Kuzniecky; A J Barkovich
Journal:  Brain Dev       Date:  2001-03       Impact factor: 1.961

2.  Electroclinical, MRI and neuropathological study of 10 patients with nodular heterotopia, with surgical outcomes.

Authors:  L Tassi; N Colombo; M Cossu; R Mai; S Francione; G Lo Russo; C Galli; M Bramerio; G Battaglia; R Garbelli; A Meroni; R Spreafico
Journal:  Brain       Date:  2004-12-23       Impact factor: 13.501

3.  The clinical and imaging features of gray matter heterotopia: a clinical analysis on 15 patients.

Authors:  Hafiz Khuram Raza; Hao Chen; Thitsavanh Chansysouphanthong; Zuohui Zhang; Fang Hua; Xinchun Ye; Wei Zhang; Liguo Dong; Shenyang Zhang; Xiaopeng Wang; Guiyun Cui
Journal:  Neurol Sci       Date:  2018-12-10       Impact factor: 3.307

4.  Development of high-resolution 3D MR fingerprinting for detection and characterization of epileptic lesions.

Authors:  Dan Ma; Stephen E Jones; Anagha Deshmane; Ken Sakaie; Eric Y Pierre; Mykol Larvie; Debra McGivney; Ingmar Blümcke; Balu Krishnan; Mark Lowe; Vikas Gulani; Imad Najm; Mark A Griswold; Z Irene Wang
Journal:  J Magn Reson Imaging       Date:  2018-12-23       Impact factor: 4.813

5.  Stereo-EEG recording and minimally invasive treatment of a periventricular nodular heterotopy: Two-in-one strategy.

Authors:  Ana Catarina Franco; Ana Rita Peralta; Carlos Morgado; António Gonçalves Ferreira; Alexandre Rainha Campos; Carla Bentes
Journal:  Clin Neurophysiol       Date:  2020-03-08       Impact factor: 3.708

6.  Quantitative Measurement of Longitudinal Relaxation Time (qT1) Mapping in TLE: A Marker for Intracortical Microstructure?

Authors:  R Edward Hogan
Journal:  Epilepsy Curr       Date:  2017 Nov-Dec       Impact factor: 7.500

7.  Periventricular nodular heterotopia and intractable temporal lobe epilepsy: poor outcome after temporal lobe resection.

Authors:  L M Li; F Dubeau; F Andermann; D R Fish; C Watson; G D Cascino; S F Berkovic; N Moran; J S Duncan; A Olivier; R Leblanc; W Harkness
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

8.  Gray matter heterotopias: MR characteristics and correlation with developmental and neurologic manifestations.

Authors:  A J Barkovich; B O Kjos
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

9.  Simultaneous T1 and T2 Brain Relaxometry in Asymptomatic Volunteers using Magnetic Resonance Fingerprinting.

Authors:  Chaitra Badve; Alice Yu; Matthew Rogers; Dan Ma; Yiying Liu; Mark Schluchter; Jeffrey Sunshine; Mark Griswold; Vikas Gulani
Journal:  Tomography       Date:  2015-12

10.  Age-Related Changes in Relaxation Times, Proton Density, Myelin, and Tissue Volumes in Adult Brain Analyzed by 2-Dimensional Quantitative Synthetic Magnetic Resonance Imaging.

Authors:  Akifumi Hagiwara; Kotaro Fujimoto; Koji Kamagata; Syo Murata; Ryusuke Irie; Hideyoshi Kaga; Yuki Someya; Christina Andica; Shohei Fujita; Shimpei Kato; Issei Fukunaga; Akihiko Wada; Masaaki Hori; Yoshifumi Tamura; Ryuzo Kawamori; Hirotaka Watada; Shigeki Aoki
Journal:  Invest Radiol       Date:  2021-03-01       Impact factor: 10.065

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.